A Phase 2 interventional study of Tissue Engineered Vascular Grafts in HLH - Hypoplastic Left Heart Syndrome, DORV and DILV - Double Inlet Left Ventricle, sponsored by Nationwide Children's Hospital. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Nationwide Children's Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Hypoplastic Left Heart Syndrome with a site in United States — 6 open to participants now, 10 under way, 1 of them phase 3. Hypoplastic Left Heart Syndrome · United States.
Among the 44 studies in Hypoplastic Left Heart Syndrome with a site in United States, this one is the 18th largest by planned enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2020, is one of 4 in phase 2, and was the 36th registered.
67 studies on the registry are indexed under Hypoplastic Left Heart Syndrome; 12 are open to participants now.
Browse Hypoplastic Left Heart Syndrome studies →6 of the 44 studies in Hypoplastic Left Heart Syndrome with a site in United States are open now. Recruiting first, the newest first:
HeartWorks, Inc. · Sites in United States
Ages 0+
Queen Silvia Children's Hospital, Gothenburg, Sweden · Sites in United States, Austria, Canada and 5 more countries
Ages 23 wk–31 wk
Children's Hospital Medical Center, Cincinnati · Sites in United States, Canada, United Kingdom
Ages up to 15 mo
Mauro H. Schenone · Sites in United States
Ages up to 45 · Women only · Healthy volunteers
Emory University · Sites in United States
Ages up to 1
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Hypoplastic Left Heart Syndrome studies recruiting now, 3 set no upper age limit and 6 stop at 75 or younger; 9 take children under 18; none take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 7 · Phase 3 2
First in 2001; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 30 across 41 interventional studies indexed under Hypoplastic Left Heart Syndrome.
Median enrollment 30 across the 26 interventional studies, 96 across the 18 observational. Of the 32 that completed or were terminated, 7 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 44 have an industry lead sponsor. The 10 most frequent:
Nationwide Children's Hospital is the lead sponsor of 233 studies on the registry; 41 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 9 (53%) have results posted.
Nationwide Children's Hospital has 1 study filed under Hypoplastic Left Heart Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 44 studies in Hypoplastic Left Heart Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A single arm clinical trial evaluating the safety and efficacy of the second generation TEVG as vascular conduits for extracardiac total cavopulmonary connection.
This investigation is a prospective, open-labeled clinical trial determining the safety of the use of tissue engineered vascular grafts as conduits for EC TCPC. Patients will be monitored for adverse events (AE) and serious adverse events (SAE). Special attention will be paid to the incidence of stenosis. We will determine graft-related morbidity and mortality for the second generation TEVGs which will include any post-operative complication such as any aneurismal dilation, stenosis, thromboembolic or infectious event that requires treatment and is thought to be caused by the graft as determined by the investigators and confirmed by the data safety monitoring board. The graft related complication rates will be compared between the first and second generation TEVGs. An interim analysis will be performed to assess the incidence of early (\<6 month) graft-related complications in the first 6 enrolled patients. Safety and tolerability will be assessed through serial imaging, to determine the effect of growth and remodeling on graft performance through echocardiography and 4-dimensional MRI. All appropriate patients requiring EC TCPC who meet study inclusion/exclusion criteria will be evaluated for enrollment in the clinical trial. All enrolled subjects will be required to have follow-up visits at Nationwide Children's Hospital for a minimum of 2 years following implant. After obtaining informed consent for the patient's parents, patients with single ventricle cardiac anomalies will undergo EC TCPC using a tissue engineered conduit. Post-operative care and monitoring will follow an established, standardized, clinical algorithm in which the patient's clinical status including complications and measurements of graft function will be serially evaluated and recorded over a two year period using physical examination, echocardiography, and MRI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients will be eligible for inclusion in the study if they meet all of the following criteria.
Exclusion Criteria:
Patients will be excluded from participation in the study if they meet any of the following criteria.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Combination Product: Tissue Engineered Vascular Grafts
Patients will undergo EC TCPC interposition grafting with a tissue engineered vascular graft and serial magnetic resonance imaging (MRI)
Safety and Tolerability of TEVG
Assessed through graft related complications as determined by serial echocardiogram
Time frame: 2 years
Safety and Tolerability of TEVG
Assessed through graft related complications as determined by serial MRI
Time frame: 2 years
Safety and Tolerability of TEVG
Assessed through adverse events
Time frame: 2 years
Efficacy of TEVG
Evaluate graft performance based on MRI
Time frame: 2 years
Efficacy of TEVG
Measured graft volume(mL) as determined by MRI
Time frame: 2 years
Efficacy of TEVG
Measured graft length (mm) as determined by MRI
Time frame: 2 years
Plan to share: Yes — Biological Samples: We plan to make available representative samples of the bone marrow-derived mononuclear cells and seeded scaffold to a NIH-designated entity (RM Innovation Catalyst) for in depth and independent characterization. Specifically, for each TEVG manufactured, 1 ml of bone marrow-derived mononuclear cells and a 5mm x 5mm section of the seeded scaffold will be sampled, packed, and transported to the RM Innovation Catalyst per their instructions. In addition, copies of the batch record and completed certificate of analysis will be forwarded to the NIH-designated laboratory.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Prior to study initiation, the US FDA will have a comprehensive description of the processes followed to assure the accuracy, reliability, integrity, availability, and authenticity of required records and signatures supporting the data reported in the CSR will be provided to the Agency for confirmation that it will support a regulatory filing for TEVG. Every 6 months throughout the study, data will be shared with RM Innovation Catalyst, with a final locked data set no later than six months prior to the end of the award. Data from our long-term follow up policy will be made available on an annual basis if requested by the RM Innovation Catalyst or the NIH.
Access criteria: De-identified data will be provided to RM Innovation Catalyst. A Clinical Study Report will be submitted to the US FDA following the International Conference on Harmonization E3 Guideline for Industry: Structure and Content of Clinical Study Reports. Summary results of the trial will be submitted to ClinicalTrial.gov within one year of the primary completion date (per regulation and NIH policy). Results of screening tests and subjects participation in the study and ongoing test results will be shared with their primary care physician and/or primary cardiologist if cardiac care is being provided outside of Nationwide Children's Hospital.
Started Jul 2020 (actual). Primary completion is estimated for Dec 2029, 113 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Aug 2026 → Dec 2029 and completion Aug 2027 → Dec 2031.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hypoplastic Left Heart Syndrome →
Nationwide Children's Hospital →